Press Room

Webinar: Commercial Reality and Lifecycle Management of ASDs

Start
Thursday, April 20, 2023 - 16:00
Location: online

This is the third session of a three-part webinar series on Amorphous Solid Dispersions by Spray Drying: From Early Formulation to Commercial Lifecycle Management.

 

Thursday, April 20th

4:00pm GMT  |  11:00 am EDT  |  5:00 pm CEST

Registrations to the webinar are subject to approval.

 

Watch On-demand. 

Gated content. Registration is required.

 

Featured Hovione experts in this webinar
Webinar Series Spray Drying Speakers - Ines Salsinha | Hovione
Webinar Series Spray Drying Speakers - Tiago Profirio | Hovione
Inês Salsinha, M.Sc.

Quality Assurance Specialist

Site QA
Tiago Porfirio, Ph.D.

R&D Manager, Particle Engineering

Corporate Technical Services 

 

After presenting Hovione’s formulation screening and scale-up methodologies for amorphous solid dispersions (ASDs) by spray drying, the webinar series will conclude by discussing the link between development, process validation and lifecycle management.

​​​​Inês Salsinha and Tiago Porfirio will explain how to perform a critical and extensive evaluation of potential failure modes, how to carry out risk assessment and how to define criticality to enable a successful Process Performance Qualification (PPQ).

Commercialization of ASDs requires statistical tools and methodologies to enable the continued process verification (CPV) application and ensure that the process remains under control. In this session, participants will gain insights into the importance of continuous improvement supported by continuous data analysis. The speakers will also outline the importance of commercial experience when using spray drying to produce ASDs. Case studies, namely regarding post approval changes, will be presented, and discussed.

 

Your Key Learning Objectives: 

  • Learn how to apply Quality Risk Management tools to get a successful Process Validation while ensuring a robust commercial stage.
  • Learn how statistical tools support the commercial lifecycle enhancing process control and product quality.
  • Discover how Continued Process Verification (CPV) and Product Quality Review (PQR) are key for a continuous improvement strategy.

 

Who Should Attend: 

This webinar is suitable for anyone working in formulation and process development of amorphous solid dispersions, procurement, and outsourcing teams or project managers, who are interested in understanding the end-to-end process for validation and commercialization of an ASD by Spray Drying.

 

Watch On-demand. 

Gated content. Registration is required.

 

 

Are you looking for a clear path from formulation screening to commercialization?

As an experienced manufacturer of ASDs by Spray Drying, Hovione will support your project by combining modeling capabilities, extensive process knowledge, and manufacturing capacity with an unmatched approval track record.

Get in touch today

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026